CH

BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme

Retrieved on: 
tisdag, juni 4, 2024
Inflammation, Therapy, Cystic Fibrosis Trust, Patient, Cystic fibrosis, MDC, Research, Bacteria, NTM, Bronchiectasis, Mucus, AMR, Infection, Discovery, LifeArc, CDP, Pharmaceutical industry

The build-up of thick sticky mucus in the lungs of people living with CF predisposes them to infections which can be difficult to clear.

Key Points: 
  • The build-up of thick sticky mucus in the lungs of people living with CF predisposes them to infections which can be difficult to clear.
  • Treatment failure due to the development of resistance is frequently seen in people living with CF, and the consequences can be devastating.
  • The discovery and development of new antimicrobials to treat infections associated with CF is an urgent unmet need.
  • Dr. Sergio Lociuro, Chief Scientific Officer of BioVersys: “We are absolutely delighted not only to have been awarded this funding from CF AMR Syndicate, but also to have them as new collaboration partners.

Geely Auto Gears up NEV Transformation and Innovation with Long-Term SiC Supply Agreement and Joint Lab with STMicroelectronics

Retrieved on: 
tisdag, juni 4, 2024
EV, Electronics, ADAS, NEVS, HKEX, JV, STM, Silicon carbide, Electronic, DC-DC, Geely, Bev, STMicroelectronics, OBC, Traction, Automotive industry

Innovation Joint Lab set up to support the development of smart, electrified and connected cars.

Key Points: 
  • Innovation Joint Lab set up to support the development of smart, electrified and connected cars.
  • Geely Auto Group has adopted ST’s third generation SiC MOSFET devices in electric traction inverters.
  • “We are pleased to have a deep cooperation with global automotive semiconductor leader STMicroelectronics to establish an innovation joint lab.
  • This long-term SiC supply agreement and the joint lab establishment mark a significant step forward in our long-established cooperation,” said Henry Cao, Executive Vice President of Sales & Marketing, China Region, STMicroelectronics.

WISe.ART Partners with Sustainable Fashion Innovation Society on Upcoming Phygital Sustainability Expo

Retrieved on: 
måndag, juni 3, 2024
WIHN, Internet of things, WKEY, ART, Partnership, Hedera, Cryptocurrency

Rome, Italy – June 3, 2024: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) innovations, operating as a holding company, announced that its subsidiary WISe.ART has partnered with Sustainable Fashion Innovation Society (“Society”) on the upcoming Phygital Sustainability Expo® (“Expo”) in Rome, Italy.

Key Points: 
  • Rome, Italy – June 3, 2024: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) innovations, operating as a holding company, announced that its subsidiary WISe.ART has partnered with Sustainable Fashion Innovation Society (“Society”) on the upcoming Phygital Sustainability Expo® (“Expo”) in Rome, Italy.
  • In addition to WISe.ART’s partnership, WISeKey’s Cybersecurity and Hedera DePIN (Decentralized Physical Infrastructure Networks) are playing crucial roles in advancing the Phygital Sustainability industry, especially in the realm of sustainable fashion.
  • On the other hand, Hedera DePIN leverages blockchain technology to enhance transparency and traceability within the fashion industry.
  • This integration not only boosts consumer confidence but also encourages brands to adopt more sustainable practices.

STMicroelectronics Announces Status of Common Share Repurchase Program

Retrieved on: 
måndag, juni 3, 2024
Treasury, STMicroelectronics, Electronics, Share repurchase, EUR, Disclosure, LEI, Security (finance)

AMSTERDAM – June 03, 2024 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021. The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.

Key Points: 
  • Disclosure of Transactions in Own Shares – Period from May 27, 2024 to May 31, 2024
    AMSTERDAM – June 03, 2024 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021.
  • The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.
  • The purpose of these transactions under article 5(2) of Regulation (EU) 596/2014 (the Market Abuse Regulation) was to meet obligations arising from debt financial instruments that are exchangeable into equity instruments.
  • Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STMicroelectronics (ISIN: NL0000226223), in detailed form.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Retrieved on: 
måndag, juni 3, 2024
Grant, Compensated emancipation, Employment

LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company’s common shares to three new employees on June 3, 2024 (each, a “Grant”).

Key Points: 
  • LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company’s common shares to three new employees on June 3, 2024 (each, a “Grant”).
  • The Grants were offered as material inducement to the employees’ employment.
  • The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company.
  • The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08.

Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year

Retrieved on: 
söndag, juni 2, 2024
Asthma, HEAD, Faculty, Patient, Conditional sentence, Congress, ELISA, Research, Work, Flow cytometry, Universidad CEU San Pablo, European, Medicine, EAACI, Allergy, Pharmaceutical industry

VALENCIA, Spain, June 02, 2024 (GLOBE NEWSWIRE) -- Allergic diseases cost between 1,823€ and 6,656€ per patient per year if we only consider the direct costs derived from healthcare, according to a study of the data collected through the European HEAD registry promoted by the EAACI, which is holding its congress at the Feria de Valencia until Monday, June 3.

Key Points: 
  • “Allergic diseases and asthma are among the most common chronic diseases worldwide and account for a considerable global health burden.
  • The HEAD registry was launched to describe patterns of care for allergic diseases and asthma and to assess their impact on costs, both financial and personal.
  • “The significant burden of allergic diseases, according to this research, calls for immediate action to improve their management,” says Dr. Agache.
  • The Congress also discusses how to facilitate the translation of trial and research results into routine clinical practice.

EAACI Congress Kicks Off in Valencia, Spain

Retrieved on: 
fredag, maj 31, 2024
Risk, Health, Obesity, Big data, Collection, Allergy, Asthma, Chairperson, Vaccine, Congress, Food, Allergic rhinitis, Biomarker, Medicine, EAACI, Immunotherapy, Quality of life, Pharmaceutical industry

VALENCIA, Spain, May 31, 2024 (GLOBE NEWSWIRE) -- The EAACI International Congress has commenced with the slogan “Revolutionizing patient care through the power of data science.” Over the next four days, experts will discuss the latest advancements in this impactful area. Allergies, which represent a significant public health issue, encompass a variety of conditions.

Key Points: 
  • VALENCIA, Spain, May 31, 2024 (GLOBE NEWSWIRE) -- The EAACI International Congress has commenced with the slogan “Revolutionizing patient care through the power of data science.” Over the next four days, experts will discuss the latest advancements in this impactful area.
  • “Antibiotics, particularly penicillin and its derivatives, are the drugs that most frequently cause allergic reactions,” says Maria Jose Torres, Secretary General of EAACI.
  • “These two prevalent health conditions significantly affect people's quality of life,” stresses André Moreira, Co-Chair of the Congress Scientific Program.
  • “We are at a time of great and promising advances, though not without challenges,” concludes Shamji.

STMicroelectronics to build the world’s first fully integrated silicon carbide facility in Italy

Retrieved on: 
fredag, maj 31, 2024
STM, Thermal conductivity, CNR, Silicon, University, Ecosystem, STMicroelectronics, Carbon, National Research Council (Italy), Silicon carbide, Semiconductor, National Research Council, Water, Electronics

Combined with the SiC substrate manufacturing facility being readied on the same site, these facilities will form ST’s Silicon Carbide Campus, realizing the Company’s vision of a fully vertically integrated manufacturing facility for the mass production of SiC on one site.

Key Points: 
  • Combined with the SiC substrate manufacturing facility being readied on the same site, these facilities will form ST’s Silicon Carbide Campus, realizing the Company’s vision of a fully vertically integrated manufacturing facility for the mass production of SiC on one site.
  • “The fully integrated capabilities unlocked by the Silicon Carbide Campus in Catania will contribute significantly to ST’s SiC technology leadership for automotive and industrial customers through the next decades,” said Jean-Marc Chery, President and Chief Executive Officer of STMicroelectronics.
  • Sustainable practices are integral to the design, development, and operation of the Silicon Carbide Campus to ensure the responsible consumption of resources including water and power.
  • Silicon Carbide (“SiC”) is a key compound material (and technology) consisting of silicon and carbon that offers several advantages over conventional silicon for power applications.

Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024

Retrieved on: 
fredag, maj 31, 2024
BST, Research fellow, EDT, Therapy, Webcast, Participation, SIX, DSM-IV codes

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024.

Key Points: 
  • Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024.
  • Participants are required to register in advance of the conference using the link provided below.
  • Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
  • In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering.

Presentation of the Congress of the European Academy of Allergy and Clinical Immunology (EAACI) to be held in Valencia from May 31 to June 3

Retrieved on: 
torsdag, maj 30, 2024
Allergy, Intelligence, Congress, Drug, Health, Asthma, Food, Fire, Vaccine, Data science, Medicine, Health care, EAACI, Immunotherapy

VALENCIA, Spain, May 30, 2024 (GLOBE NEWSWIRE) -- Under the theme "Revolutionizing Patient Care through the Power of Data Science," the congress will highlight the crucial role of Allergy and Clinical Immunology in advancing personalised care, data science, and a holistic approach to health.

Key Points: 
  • VALENCIA, Spain, May 30, 2024 (GLOBE NEWSWIRE) -- Under the theme "Revolutionizing Patient Care through the Power of Data Science," the congress will highlight the crucial role of Allergy and Clinical Immunology in advancing personalised care, data science, and a holistic approach to health.
  • Kindly be invited to the press conference presenting the Congress of the European Academy of Allergy and Clinical Immunology (EAACI), which will bring together the world's leading allergy and clinical immunology specialists in Valencia from May 31 to June 3.
  • The press conference will occur on Friday, May 31, at 11:00 am in the Almeria Hall, Pavilion 2, Feria Valencia (Av.
  • The press conference will be conducted in English.